拜耳集团Bayer AG (BAYZF) 2009年年度报告「OTC」.pdf

1、 Key Data.2 Credo.3 Chairmans Letter.4 Board of Management.8 Report of the Supervisory Board.10investor information Bayer Stock and Bonds.14BaYer maGaZine Healthy Circulation.20 Plants of the Future.26 Visions with Films.32 Highlights 2009.38 comBined manaGement reportof the BaYer Group and BaYer aG

2、.44 consolidated financial statements of the BaYer Group .137further information Governance Bodies.256 Organization Chart.259 List of Tables and Graphics.260 Glossary.263 Index.268 Global Commitment to Sustainability .270 The Bayer Group .271 At Home Throughout The World .272 Five-Year Financial Sum

3、mary .273 Financial Calendar,Masthead,Disclaimer.274a n n u a l r e p o r t 2009 For direct access to a chapter,simply click on its name.cover pictureAs an inventor company Bayer aims for innovation,supported by its 12,400-strong global research and development team.One member of that team is Dr.Xin

4、 Ma,Head of the Global Drug Discovery Innovation Center China in Beijing.The photo shows the scientist preparing an experiment during drug development.2bayer annual report 2009Key Data table 1.1 20082009Change million million%bayer GroupSales32,91831,168 5.3EBITDA16,2665,815 7.2EBITDA before special

5、 items6,9316,472 6.6EBITDA margin before special items21.1%20.8%EBIT 23,5443,006 15.2EBIT before special items4,3423,772 13.1Income before income taxes2,3561,870 20.6Net income1,7191,359 20.9Earnings per share()32.221.70 23.4Core earnings per share()44.173.64 12.7Gross cash flow 55,2954,658 12.0Net

6、cash flow 63,6085,375+49.0Net financial debt14,1529,691 31.5Capital expenditures as per segment table1,9821,669 15.8Research and development expenses2,6532,746+3.5Dividend per Bayer AG share()1.401.400.0bayer HealthCare External sales15,40715,988+3.8EBITDA13,6924,148+12.4EBITDA before special items4